Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis -: Results of a randomized trial

被引:118
作者
Ciulla, MM
Paliotti, R
Esposito, A
Diez, J
López, BA
Dahlóf, B
Nicholls, G
Smith, RD
Gilles, L
Magrini, F
Zanchetti, A
机构
[1] Univ Milan, Osped Maggiore, IRCCS, Ctr Interuniv Fisiol Clin & Ipertens, I-20122 Milan, Italy
[2] Univ Milan, Osped Maggiore, IRCCS, Ist Med Cardiovasc, I-20122 Milan, Italy
[3] Univ Navarra, E-31080 Pamplona, Spain
[4] Univ Gothenburg, Ostra Univ Hosp, Gothenburg, Sweden
[5] UAE Univ, Dept Internal Med, Al Ain, U Arab Emirates
[6] Merck & Co Inc, Whitehouse Stn, NJ USA
[7] Merck & Co Inc, Brussels, Belgium
[8] IRCCS, Ist Auxol Italiano, Milan, Italy
关键词
hypertension; myocardium; collagen; angiotensin;
D O I
10.1161/01.CIR.0000137118.47943.5C
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis. Methods and Results - We compared the effects of an angiotensin II receptor antagonist with a beta-blocker on myocardial collagen volume (assessed by echoreflectivity and serum collagen markers) in 219 hypertensive patients with echocardiographically documented LVH. Patients were allocated randomly to receive losartan 50 to 100 mg/d (n = 111) or atenolol 50 to 100 mg/d (n = 99) with or without hydrochlorothiazide 12.5 to 25 mg/d for 36 weeks. Echoreflectivity analysis was conducted on ultrasound tracings of the midapex septum with specifically designed and validated software. A color histogram of reflecting echoes was obtained, and its spread (broadband [BB], previously shown to correlate directly with collagen volume fraction on endomyocardial biopsies) was used as the primary outcome measure. Mean color scale and serum markers of collagen synthesis (PIP, PIIIP) or degradation (CITP) were secondary outcome variables. Echoreflectivity analysis proved feasible in 106 patients (losartan 52, atenolol 54). Losartan reduced BB over 36 weeks (from 114.5 to 104.3 color levels, P < 0.02), whereas atenolol treatment was associated with an increase in BB (from 109.0 to 113.6 color levels, P = NS), the difference between treatments being -12.8 color levels (95% CI -23.6 to -2.0, P = 0.02). Secondary end points (mean color scale and collagen markers) also changed in the direction of decreased collagen in patients receiving losartan, but differences between groups were not statistically significant. Conclusions - In hypertensive patients with LVH, losartan decreases myocardial collagen content, whereas atenolol does not. The difference between the 2 treatments is statistically significant.
引用
收藏
页码:552 / 557
页数:6
相关论文
共 29 条
[1]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[2]   Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease [J].
Brilla, CG ;
Funck, RC ;
Rupp, H .
CIRCULATION, 2000, 102 (12) :1388-1393
[3]   CARDIOREPARATIVE EFFECTS OF LISINOPRIL IN RATS WITH GENETIC-HYPERTENSION AND LEFT-VENTRICULAR HYPERTROPHY [J].
BRILLA, CG ;
JANICKI, JS ;
WEBER, KT .
CIRCULATION, 1991, 83 (05) :1771-1779
[4]   Advanced hypertensive heart disease in spontaneously hypertensive rats - Lisinopril-mediated regression of myocardial fibrosis [J].
Brilla, CG ;
Matsubara, L ;
Weber, KT .
HYPERTENSION, 1996, 28 (02) :269-275
[5]   COLLAGEN-METABOLISM IN CULTURED ADULT-RAT CARDIAC FIBROBLASTS - RESPONSE TO ANGIOTENSIN-II AND ALDOSTERONE [J].
BRILLA, CG ;
ZHOU, GP ;
MATSUBARA, L ;
WEBER, KT .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1994, 26 (07) :809-820
[6]   Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs [J].
Brilla, CG .
CARDIOVASCULAR RESEARCH, 2000, 46 (02) :324-331
[7]   Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization [J].
Ciulla, M ;
Paliotti, R ;
Hess, DB ;
Tjahja, E ;
Campbell, SE ;
Magrini, F ;
Weber, KT .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 1997, 10 (06) :657-664
[8]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[9]   Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy [J].
Dahlof, B ;
Zanchetti, A ;
Diez, J ;
Nicholls, MG ;
Yu, CM ;
Barrios, V ;
Aurup, P ;
Smith, RD ;
Johansson, M .
JOURNAL OF HYPERTENSION, 2002, 20 (09) :1855-1864
[10]   Incremental value of ultrasonic tissue characterization (backscatter) in the evaluation of left ventricular myocardial structure and mechanics in essential arterial hypertension [J].
Di Bello, V ;
Giorgi, D ;
Talini, E ;
Dell'Omo, G ;
Palagi, C ;
Romano, MF ;
Pedrinelli, R ;
Mariani, M .
CIRCULATION, 2003, 107 (01) :74-80